3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
14
Leukemia, Myeloid, Acute
8
Triple Negative Breast Neoplasms
3
Leukemia
3
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Primary Breast Cancer
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid
1
HER2-negative Breast Cancer
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
eribulin
3
Vinorelbine
2
Paclitaxel
2
Epirubicin
2
Doxorubicin
2
Cyclophosphamide
2
trastuzumab deruxtecan
1
tislelizumab
1
taxane
1
sacituzumab govitecan
1
pembrolizumab
1
pamiparib
1
liposomal doxorubicin
1
camrelizumab
1
anlotinib
1
Taxes
1
Precision Medicine
1
Gemcitabine
1
Docetaxel
1
Cisplatin
1
Carboplatin
1
Capecitabine
1
Anthracyclines
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
HER2-negative Breast Cancer
×
Anthracyclines
×
Clear all
NCT06102824
2024-11-25
ORIENTA
Guangdong Provincial People's Hospital
Phase 2
Recruiting
252 enrolled